InvestorLens

NAMS — NEWAMSTERDAM PHARMA COMPANY

Public company

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About NEWAMSTERDAM PHARMA COMPANY (NAMS)

NEWAMSTERDAM PHARMA COMPANY (NAMS) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Andreas Halvorsen (Viking Global Investors), valued at $147M. Across recent filings, tracked investors recorded 3 new positions, 1 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in NAMS

100
/100
Strong Institutional Accumulation
Added / Increased4
Reduced0
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track NAMS

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

NAMS Ownership Composition

How NEWAMSTERDAM PHARMA COMPANY is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
100% of tracked value
Institutions
5
tracked investors
Total Reported
$268.3M
combined 13F value
Sectors2
  • Other99.6%
  • Hedge Funds0.4%
Other(4)
99.6%
Hedge Funds(1)
0.4%

Tracked investors reporting NAMS

  • Andreas HalvorsenMar 31, 2026
    Viking Global Investors
    Shares
    4.2M
    Value
    $134.6M
    % Portfolio
    0.38%
  • Stanley DruckenmillerMar 31, 2026
    Duquesne Family Office
    Shares
    3.1M
    Value
    $98.3M
    % Portfolio
    2.91%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    767.1K
    Value
    $24.6M
    % Portfolio
    0.00%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    303.8K
    Value
    $9.7M
    % Portfolio
    0.00%
  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    36.4K
    Value
    $1.2M
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold NAMS?
5 tracked institutional investors disclosed a position in NAMS (NEWAMSTERDAM PHARMA COMPANY) in their most recent 13F filing.
Who is the largest institutional holder of NAMS?
Andreas Halvorsen, Viking Global Investors, holds the largest disclosed position in NAMS, valued at $147M.
Did institutional ownership of NAMS increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 1 increased, 0 reduced, and 0 fully exited NAMS.
Where does this NAMS ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
NAMS (NEWAMSTERDAM PHARMA COMPANY) — Institutional Holders — InvestorLens